HER2-targeted monoclonal antibodies (trastuzumab, pertuzumab, trastuzumab emtansine [T-DM1], trastuzumab-deruxtecan) play a crucial role in treating HER2-positive breast cancer, both in early and metastatic stages. The gene discussed is ERBB2; the disease is breast cancer.